GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (NAS:IMNN) » Definitions » Cyclically Adjusted Revenue per Share

Imunon (Imunon) Cyclically Adjusted Revenue per Share : $0.00 (As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Imunon Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Imunon's adjusted revenue per share for the three months ended in Dec. 2023 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Imunon's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Imunon was -12.20% per year. The lowest was -58.90% per year. And the median was -50.50% per year.

As of today (2024-04-28), Imunon's current stock price is $1.44. Imunon's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $0.00. Imunon's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Imunon was 6.79. The lowest was 0.29. And the median was 1.18.


Imunon Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Imunon's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imunon Cyclically Adjusted Revenue per Share Chart

Imunon Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.42 23.56 3.33 3.20 -

Imunon Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.20 - - - -

Competitive Comparison of Imunon's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Imunon's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imunon's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imunon's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Imunon's Cyclically Adjusted PS Ratio falls into.



Imunon Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Imunon's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/129.4194*129.4194
=0.000

Current CPI (Dec. 2023) = 129.4194.

Imunon Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 1.603 99.695 2.081
201406 1.506 100.560 1.938
201409 1.506 100.428 1.941
201412 1.136 99.070 1.484
201503 1.316 99.621 1.710
201506 1.250 100.684 1.607
201509 1.136 100.392 1.464
201512 1.126 99.792 1.460
201603 1.126 100.470 1.450
201606 1.087 101.688 1.383
201609 0.940 101.861 1.194
201612 0.926 101.863 1.177
201703 1.126 102.862 1.417
201706 0.283 103.349 0.354
201709 0.233 104.136 0.290
201712 0.109 104.011 0.136
201803 0.106 105.290 0.130
201806 0.106 106.317 0.129
201809 0.105 106.507 0.128
201812 0.104 105.998 0.127
201903 0.098 107.251 0.118
201906 0.091 108.070 0.109
201909 0.087 108.329 0.104
201912 0.073 108.420 0.087
202003 0.073 108.902 0.087
202006 0.063 108.767 0.075
202009 0.055 109.815 0.065
202012 0.049 109.897 0.058
202103 0.073 111.754 0.085
202106 0.022 114.631 0.025
202109 0.022 115.734 0.025
202112 0.022 117.630 0.024
202203 0.022 121.301 0.023
202206 0.018 125.017 0.019
202209 0.018 125.227 0.019
202212 0.014 125.222 0.014
202303 0.000 127.348 0.000
202306 0.000 128.729 0.000
202309 0.000 129.860 0.000
202312 0.000 129.419 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Imunon  (NAS:IMNN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Imunon was 6.79. The lowest was 0.29. And the median was 1.18.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Imunon Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Imunon's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Imunon (Imunon) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (NAS:IMNN) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
Executives
James E Dentzer director C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Le Goff Corinne director, officer: President and CEO 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Michael H Tardugno officer: Chief Executive Offier 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046-2364
Frederick J. Fritz director C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Kardaras Constantine John officer: Chief Accounting Officer C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE100, LAWRENCEVILLE NJ 08648
Christine A Pellizzari director 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Stacy Lindborg director C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Donald P Braun director C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Alberto R Martinez director C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Jeffrey Wayne Church officer: Chief Financial Officer
Robert W Hooper director C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Andreas Voss director C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Egwu, Inc. Fka Egen, Inc. 10 percent owner 601 GENOME WAY, SUITE 3400, HUNTSVILLE AL 35806
Khursheed Anwer officer: Chief Scientific Officer C/O CELSION CORPORATION, 997 LENOX DRVIE, SUITE 100, LAWRENCEVILLE NJ 08648
Gregory L Weaver director 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107

Imunon (Imunon) Headlines

From GuruFocus